Delays in Anti-Hyperglycemic Therapy Initiation and Intensification are Associated with Cardiovascular Events, Heart Failure Hospitalizations, and All-Cause Mortality

Diabetes - GeneralGlycemic Control

A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative

Metabolism.

Mongraw-Chaffin M, LaCroix AZ, Sears DD, Garcia L, Phillips LS, Salmoirago-Blotcher E, Zaslavsky O, Anderson CA

doi: 10.1016/

Diabetes - GeneralType 2 Diabetes

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME^® trial

Eur Heart J.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Erik Johansen O, Inzucchi SE

Diabetes - General

In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry.

Eur J Heart Fail.

Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, Drozdz J, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro MG, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L

doi: 10.1002/ejhf.679.

Type 2 Diabetes

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

J Am Heart Assoc

Thomsen RW, Knudsen JS, Kahlert J, Baggesen LM, Lajer M, Holmgaard PH, Vedin O, Ustyugova A, Sørensen HT

doi: 10.1161/JAHA.120.019356

COMMENTED

Diabetes - General

Statin therapy for primary prevention in the elderly and its association with new-onset diabetes, cardiovascular events and all-cause mortality

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Am J Med

Lavie G, Hoshen M, Leibowitz M, Benis A, Akriv A, Balicer R, Reges O

doi: 10.1016/j.amjmed.2020.09.058

COMMENTED

Diabetes - GeneralGlycemic Control

The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes

Diabetes Care.

Lee AK, Warren B, Lee CJ, McEvoy JW, Matsushita K, Huang ES, Sharrett AR, Coresh J, Selvin E

doi: 10.2337/dc17-1669.

Type 2 Diabetes

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study

Diabetes Obes Metab.

Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T

doi: 10.1111/dom.14074.

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia

Diabetes Res Clin Pract.

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW

doi: 10.1016/j.diabres.2016.12.004.

Related content